Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.

Apostolia Maria Tsimberidou*, Francis J. Giles, Madeleine Duvic, Razelle Kurzrock

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


BACKGROUND: Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL). OBJECTIVE: To assess the toxicity, safety, and efficacy of etanercept (soluble TNF receptor) in patients with relapsed CTCL. METHODS: Etanercept was administered twice weekly at a dose of 25 mg subcutaneously. Patients with improvement after two months could be continued on treatment. RESULTS: Twelve out of the 13 patients enrolled on study were evaluable (Stage I-IIA, 3 patients; Stage IIB-IV disease, 9 patients). The median number of previous therapies was 7 (range, 3-12). Etanercept induced partial remission in one patient (8%) and minor response in one patient (8%), both of whom had Stage IB disease. Most patients experienced no side effects. CONCLUSION: This pilot study suggests that etanercept is safe and generally well tolerated in patients with CTCL. The effect of etanercept in a larger cohort of patients with early disease merits investigation.

Original languageEnglish (US)
Pages (from-to)200-204
Number of pages5
JournalJournal of the American Academy of Dermatology
Issue number2
StatePublished - Aug 2004

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.'. Together they form a unique fingerprint.

Cite this